Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Drug safety watch: tracking side effects in Tough-to-Treat prostate cancer

NCT ID NCT06733337

Summary

This study is monitoring the safety and side effects of the drug Talzenna in men with a specific, advanced form of prostate cancer. It involves men whose cancer has spread and continues to grow despite low hormone levels, and who have a specific genetic change (BRCA mutation). The main goal is to track any health problems that occur while patients take the drug over a year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Pfizer Japan

    Tokyo, Japan

Conditions

Explore the condition pages connected to this study.